Front. Oncol.Frontiers in OncologyFront. Oncol.2234-943XFrontiers Media S.A.10.3389/fonc.2023.1257404OncologyCorrectionCorrigendum: Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxelXiaMingyue†WangShuyan†QiYannan†LongKailiLiEnjieHeLingfengPanFeiyanGuoZhigangHuZhigang*Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, China
Edited and Reviewed by: Jill Kolesar, University of Kentucky, United States
*Correspondence: Zhigang Hu, huzg_2000@126.com
†These authors have contributed equally to this work
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A corrigendum on Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel by Xia M, Wang S, Qi Y, Long K, Li E, He L, Pan F, Guo Z and Hu Z (2022) Front. Oncol. 12:993243. doi: 10.3389/fonc.2022.993243OGTchemotherapydocetaxelmiR-140prostate cancersection-in-acceptanceCancer Molecular Targets and Therapeutics
Error in Figure/Table
In the published article, there was an error in Figure 2C as published. The panel in the bottom left of the figure was misused due to an error in the final assembly of Figure 2. The corrected Figure 2C and its caption “Knockdown of OGT sensitizes PC3 and DU145 cells to docetaxel” appear below.
Knockdown of OGT sensitizes PC3 and DU145 cells to docetaxel. (A) The down-regulation of OGT and O-GlcNAC by sh-OGT plasmids was detected by Western blotting. (B) CCK8 assays using OGT-KD stable cell lines treated with docetaxel in PC3 and DU145. Data are expressed as the mean ± standard deviation (SD), n=3 per group. (C) Knockdown of OGT sensitizes PC3 and DU145 cells to docetaxel. (D) Annexin V/PI staining and flow cytometry assay of control or OGT-KD cells with different drug treatments. (E) Western blot (WB) analysis of BAX and caspase-3 in control or OGT-KD PC3 and DU145 cells treated with various concentrations of docetaxel. All statistical data are presented as the mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001 (Student’s t-test).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.